Evidence map›Paper›PMID 29500681›Full record

ArticleActa neurologica Belgica2018

Correction to: Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.

Catherine Lambert, Benedicte Dubois, Dominique Dive, Andreas Lysandropoulos, Dominik Selleslag, Ludo Vanopdenbosch, Vincent Van Pesch, Bart Vanwijmeersch, Ann Janssens

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neurologica Belgica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 1 country.

Catherine LambertDepartment of Hematology, Cliniques Universitaires St Luc, Brussels, Belgium. catherine.lambert@uclouvain.be.ORCID 0000-0003-2222-0357
Benedicte DuboisDepartment of Neurology, Universitaire Zienkenhuis Leuven, Leuven, Belgium.
Dominique DiveDepartement of Neurology, CHU Liège, Esneux, Belgium.
Andreas LysandropoulosNeuroimmunology - MS Unit, Neurology Department, CUB- Hôpital Erasme, Brussels, Belgium.
Dominik SelleslagDepartment of Hematology, AZ Sint-Jan, Brugge, Belgium.
Ludo VanopdenboschDepartment of Neurology, AZ Sint Jan, Brugge, Belgium.
Vincent Van PeschDepartment of Neurology, Cliniques Universitaires St Luc, Brussels, Belgium.
Bart VanwijmeerschDepartement of Neurology, Rehabilitation and MS Center, Overpelt, Belgium.
Ann JanssensDepartment of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium.
AZ Sint-Jan · BECliniques Universitaires Saint-Luc · BEUniversitair Ziekenhuis Leuven · BEErasmus Hospital · BENational MS Center MelsbroekUniversity of Liège · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The article Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus, written by Lambert et al., was originally published electronically on the publisher's internet portal on 27 January 2018 without open access.

Identifiers

PMID29500681
PMCPMC6828241
OpenAlexW2794155494

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.